LOS ANGELES, May 14 (Reuters) - Bristol-Myers Squibb Co (BMY.N) said on Thursday that interim results from two mid-stage studies of its leukemia drug Sprycel show that it could have potential as a treatment for a certain type of advanced prostate cancer.
The company has already launched a pivotal-stage trial of the drug, in combination with chemotherapy, as a treatment for prostate cancer patients who have stopped responding to hormonal therapy.
Sprycel is currently approved for treating adults with resistance or intolerance to prior therapy for chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Bristol-Myers said two Phase 2 studies of Sprycel as a treatment for castrate-resistant prostate cancer confirmed the drug’s anti-tumor and anti-osteoclast activity with manageable side effects.
The full data will be presented at the American Society for Clinical Oncology annual meeting which starts later this month in Orlando.
The results show that Sprycel has a treatment role “above and beyond hematological cancers,” said Renzo Canetta, head of oncology research at Bristol-Myers. (Reporting by Deena Beasley; editing by Carol Bishopric),